ArticleApplied microbiology and biotechnology2021
Antidepressant-like effect of Ganoderma lucidum spore polysaccharide-peptide mediated by upregulation of prefrontal cortex brain-derived neurotrophic factor.
Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Acute neurotoxicity in a child following multi-component medicinal fungi supplementation: a case report.BMC complementary medicine and therapies · 2026Article
- Using Plant-Derived Polysaccharides in the Management of Cognitive Disorders: Molecular and Clinical Perspectives.Nutrients · 2026Review
- Exploring the Anticonvulsant and Neuropreventive Effects of Ganoderma lucidum Extract in the Pentylenetetrazole-Kindling Model: Analysis of Cognitive Comorbidities Associated with Epilepsy.Neurochemical research · 2026Article
- Sexual spores in mushrooms: bioactive compounds, factors and molecular mechanisms of spore formation.Archives of microbiology · 2025Review
- Bioactive compounds from Chinese herbal plants for neurological health: mechanisms, pathways, and functional food applications.Frontiers in nutrition · 2025Review
- Therapeutic efficacy of a galactoglucan fromFrontiers in nutrition · 2025Article
- Developmental and reproductive toxicity assessment of sporoderm-removedFrontiers in cell and developmental biology · 2025Article
- Danggui Shaoyao San attenuates depressive-like behaviors in mice via TLR4/NF-κB p65/JAK-STAT3/AKT-GSK3β signaling pathways: modulation of hippocampal neurogenesis and neuroinflammation.Frontiers in nutrition · 2025Article
- Evaluation of Two Different Treatments for Larch Logs as Substrates to CultivateLife (Basel, Switzerland) · 2024Article
- MiR-10b-5p attenuates spinal cord injury and alleviates LPS-induced PC12 cells injury by inhibiting TGF-β1 decay and activating TGF-β1/Smad3 pathway through PTBP1.European journal of medical research · 2024Article
- A review of the pharmacological action and mechanism of natural plant polysaccharides in depression.Frontiers in pharmacology · 2024Review
- A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity.Frontiers in pharmacology · 2024Article
- A Neutral Polysaccharide from Spores ofInternational journal of molecular sciences · 2023Article
- Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review.Antioxidants (Basel, Switzerland) · 2023Review
- Antioxidant activity and cytotoxicity of exopolysaccharide from mushroomBiomass conversion and biorefinery · 2022Article
- Edible Mushrooms as a Potential Component of Dietary Interventions for Major Depressive Disorder.Foods (Basel, Switzerland) · 2022Review
- Potential neuroprotective and anticonvulsant effects ofFrontiers in neurologyArticle
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
A 28-kDa polysaccharide-peptide (PGL) with antidepressant-like activities was isolated from spores of the mushroom Ganoderma lucidum. It was unadsorbed on DEAE-cellulose. Its internal amino acid sequences manifested pronounced similarity with proteins from the mushrooms Lentinula edodes and Agaricus bisporus. The monosaccharides present in 28-kDa PGL comprised predominantly of glucose (over 90%) and much fewer galactose, mannose residues, and other residues. PGL manifested antidepressant-like activities as follows. It enhanced viability and DNA content in corticosterone-injured PC12 cells(a cell line derived from a pheochromocytoma of the rat adrenal medulla with an embryonic origin from the neural crest containing a mixture of neuroblastic cells and eosinophilic cells) and reduced LDH release. A single acute PGL treatment shortened the duration of immobility of mice in both tail suspension and forced swimming tests. PGL treatment enhanced sucrose preference and shortened the duration of immobility in mice exposed to chronic unpredictable mild stress (CUMS). Chronic PGL treatment reversed the decline in mouse brain serotonin and norepinephrine levels but did not affect dopamine levels. PGL decreased serum corticosterone levels and increased BDNF mRNA and protein levels and increased synapsin I and PSD95 levels in the prefrontal cortex. This effect was completely blocked by pretreatment with the BDNF antagonist K252a, indicating that PGL increased synaptic proteins in a BDNF-dependent manner.Key points• An antidepressive polysaccharide-peptide PGL was isolated from G. lucidum spores.• PGL protected PC12 nerve cells from the toxicity of corticosterone.• PGL upregulated BDNF expression and influenced key factors in the prefrontal cortex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.